Pacific Biosciences of California: the 2024 slump and hopes for a turnaround
Pacific Biosciences of California $PACB, a leader in long-read gene sequencing, saw its stock value drop dramatically by 81% in 2024 . Yet there is potential in this risky investment, as evidenced by the continued interest of prominent investor Cathie Wood, who continues to buy PacBio stock.
I don't like this, and there are exactly the things/factors that deter me from investing in it.